Compare FedEx Corporation (FDX) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs McKesson Corporation — how do they compare? FedEx Corporation trades at $292.44 (market cap $69.04B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is the larger of the two by market cap, and FedEx Corporation pays the higher dividend (1.67%). Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and McKesson Corporation for 74 Days on average.
| FDX | MCK | |
|---|---|---|
Market Cap | $69.04B | $108.46B |
Volume | 1,287,367 | 712,607 |
Sector | Industrials | Health |
52-Week High | $339.35 | $995.69 |
52-Week Low | $180.87 | $725.17 |
Typical Hold Time | 87 Days | 74 Days |
Enterprise Value | $98.68B | $115.00B |
Dividend Yield | 1.67% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FDX trades at $289.04, flat on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68% and a P/E ratio of 15.58. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation at the annual meeting.
The outlook is mixed, with strong analyst buy consensus (57%) and a price target of $307.55 offering upside potential, but risks from rising fuel costs and a bearish technical trend suggest near-term volatility. Earnings beats in recent quarters support fundamental strength, yet macroeconomic pressures on logistics margins warrant caution.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
